Arrowhead Pharmaceuticals, Inc. (ARWR)
| Market Cap | 6.09B +6.8% |
| Revenue (ttm) | 450.82M -45.6% |
| Net Income | -724.21M |
| EPS | -5.11 |
| Shares Out | 141.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,421,436 |
| Open | 42.72 |
| Previous Close | 42.99 |
| Day's Range | 42.39 - 44.03 |
| 52-Week Range | 37.06 - 95.49 |
| Beta | 1.37 |
| Analysts | Strong Buy |
| Price Target | 105.86 (+145.56%) |
| Earnings Date | Nov 12, 2026 |
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene ... [Read more]
Financial Performance
In fiscal year 2026, Arrowhead Pharmaceuticals's revenue was $450.82 million, a decrease of -45.65% compared to the previous year's $829.45 million. Losses were -$724.21 million, 44302.6% more than in 2025.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for ARWR stock is "Strong Buy." The 12-month stock price target is $105.86, which is an increase of 145.56% from the latest price.
News
Arrowhead Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
REDEMPLO’s sHTG application could receive a decision in the March-April timeframe, supported by strong triglyceride and pancreatitis data. 2027 catalysts include ARO-DIMER and ARO-MAPT data, plus a potential zodasiran NDA filing.
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 22, 2026, the Compensat...
Arrowhead price target lowered to $105 from $108 at Citi
Citi lowered the firm’s price target on Arrowhead (ARWR) to $105 from $108 and keeps a Buy rating on the shares. The firm updated the company’s model post the fiscal…
Arrowhead price target lowered to $106 from $120 at Morgan Stanley
Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Arrowhead (ARWR) to $106 from $120 and keeps an Overweight rating on the shares.
Arrowhead price target lowered to $96 from $104 at Stifel
Stifel lowered the firm’s price target on Arrowhead (ARWR) to $96 from $104 and keeps a Buy rating on the shares.
Arrowhead Pharmaceuticals Earnings Call Transcript: Q4 2026
FY26 revenue was $450.8M and net loss was $724.2M, including a one-time $215M PRV expense. REDEMPLO demand grew as preparations advanced for a potential Q2 2027 SHTG launch, while clinical programs delivered notable RNAi milestones.
Arrowhead Pharmaceuticals Earnings release: Q4 2026
Arrowhead Pharmaceuticals released its Q4 2026 earnings on November 12, 2026, summarizing the period's financial results.
Arrowhead Pharmaceuticals Annual report: Q4 2026
Arrowhead Pharmaceuticals has published its Q4 2026 annual report on November 12, 2026.
Arrowhead reports FY26 EPS ($5.11) vs ($3.51) last year
Reports FY26 revenue $450.72M, consensus $464.14M. “Arrowhead (ARWR) has fundamentally changed over the past 12 months. Where there was once a company that relied solely on great scientific promise, t...
Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2026 fiscal year ended September 30, 2026. The Company is hosting ...
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming investor events:2026 Jefferies...
Arrowhead presents results on two of RNAi based therapies in pipeline at AHA
Arrowhead (ARWR) Pharmaceuticals presented results on two of the RNA interference, RNAi, based therapies in its cardiometabolic pipeline at the American Heart Association, AHA, Scientific Sessions 202...
Arrowhead Pharmaceuticals Presents Plozasiran Data Highlighting Sustained Triglyceride Reductions and Reduced Acute Pancreatitis Rates
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today presented results on two of the RNA interference (RNAi) based therapies in its cardiometabolic pipeline at the A...
Arrowhead refinances existing credit facility
Arrowhead (ARWR) Pharmaceuticals has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases ...
Arrowhead Pharmaceuticals Refinances Existing Credit Facility, Lowering Borrowing Costs and Extending Maturity
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs...
Arrowhead Pharmaceuticals to Webcast 2026 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its f...
Arrowhead Pharmaceuticals to Present Important Clinical Data at the American Heart Association Scientific Sessions 2026
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it will present important data at this week's American Heart Association Scientific Sessions in C...
Adults Living with Familial Chylomicronaemia Syndrome (FCS) in England and Wales Have REDEMPLO® (Plozasiran) as a New Treatment Option to Reduce Triglycerides
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that adults in England and Wales who live with a rare metabolic condition called Familial Chylomicrona...
Arrowhead assumed with a Buy at UBS
UBS analyst Joon Lee assumed coverage of Arrowhead (ARWR) with a Buy rating with a price target of $109, up from $63. The company’s lead drug, Redemplo, reported positive Phase…
Arrowhead Pharmaceuticals Transcript: Study update
After an initial loading dose, ARO-MAPT reduced mean CSF total tau by up to 73% in healthy volunteers, with no serious treatment-emergent AEs reported. Multiple-dose and Alzheimer’s patient updates are planned for 2027.
Arrowhead Pharmaceuticals Slides: Study update
Arrowhead Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on October 14, 2026.
Arrowhead Pharmaceuticals Press release: Study update
Arrowhead Pharmaceuticals issued a press release on October 14, 2026, disclosing material business information to investors.
Arrowhead announces interim results from ongoing Phase 1/2a study of ARO-MAPT
Arrowhead (ARWR) Pharmaceuticals announced interim results from an ongoing Phase 1/2a study of ARO-MAPT, the company’s investigational RNA interference, RNAi, therapeutic being developed as a potentia...